Summation
- Febbo was a professor of medicine and urology at the University of California, San Francisco Medical Center, and prior to that he was an associate professor of medicine and molecular genetics and microbiology at Duke University School of Medicine.
- Prior to that, he was chief medical officer for Genomic Health, where he oversaw the development and expansion of the company's test portfolio, including the evidence demonstrating clinical validity and clinical utility in order to drive reimbursement.
- Febbo, a distinguished industry and academic leader, will lead Veracyte's global team of research and development, medical affairs, clinical affairs, quality, regulatory affairs, and lab director professionals to help advance novel tests that address important unmet patient-care needs in cancer.
Veracyte, Inc. (Nasdaq: VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer. Dr. Febbo, a distinguished industry and academic leader, will lead Veracyte’s global team of research and development, medical affairs, clinical affairs, quality, regulatory affairs, and lab director professionals to help advance novel tests that address important unmet patient-care needs in cancer. He will report to Marc Stapley, Veracyte’s chief executive officer.
“Phil is an exceptional leader with a strong track record of driving successful commercialization of molecular tests through evidence development, guideline inclusion and key opinion leader support,” said Mr. Stapley. “His experience and expertise will be critical to further enhancing our ability to serve our customers and, ultimately, to transforming cancer care for patients all over the world.”
Phillip G Febbo has more than 25 years of experience across academia and industry. He most recently served as chief medical officer for Illumina where he built the medical team and led the successful strategy to engage clinical customers. Prior to that, he was chief medical officer for Genomic Health, where he oversaw the development and expansion of the company’s test portfolio, including the evidence demonstrating clinical validity and clinical utility in order to drive reimbursement. Before Genomic Health, Dr. Febbo was a professor of medicine and urology at the University of California, San Francisco Medical Center, and prior to that he was an associate professor of medicine and molecular genetics and microbiology at Duke University School of Medicine. He currently serves on the board of the Reagan Udall Foundation for the U.S. Food and Drug Administration (FDA). Dr. Febbo holds a B.A. in Biology from Dartmouth College and earned his M.D. from the University of California, San Francisco. He completed his internal medicine residency at Brigham and Women’s Hospitaland his medical oncology fellowship at the Dana Farber Cancer Institute.
“Cancer mortality rates have started to improve due to better detection and management. Veracyte has distinguished itself with its high-performing tests that are helping physicians use underlying biology of an individual’s cancer to make personalized management decisions that improve patient outcomes and healthcare efficiencies,” said Dr. Febbo. “I am thrilled to join the company’s talented team and to help advance the future of insight-driven care.”
